Haematopoietic stem and progenitor cell-targeted therapies for thrombocytopenia

Expert Opinion on Biological Therapy

Volumn 6, Issue 10, 2006, Pages 983-992

  Szilvassy, Stephen J ^a  

^a AMGEN INC   (United States)

Author keywords

Haematopoietic stem cells; Thrombocytopenia; Thrombopoietin; TPO receptor ligands

Indexed keywords

AF 13948; AMG 531; ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYTOKINE RECEPTOR AGONIST; ELTROMBOPAG; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; INTERLEUKIN 1ALPHA; JTZ 132; LEUKEMIA INHIBITORY FACTOR; RECOMBINANT INTERLEUKIN 11; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; RHESUS D ANTIBODY; SB 394725; SB 559475; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANEMIA; ARTHRALGIA; BACKACHE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG STRUCTURE; DYSPNEA; EDEMA; FLUID RETENTION; HEADACHE; HEART PALPITATION; HEMATOPOIETIC STEM CELL; HUMAN; MEGAKARYOPOIESIS; NONHUMAN; OSTEOPOROSIS; REVIEW; SIDE EFFECT; SORE THROAT; SPLENECTOMY; STEM CELL; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

ANIMALS; BLOOD PLATELETS; CELL DIFFERENTIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; STEM CELLS; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 33749322757     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.10.983     Document Type: Review

References (88)

1. BOTTIGER LE, WESTERHOLM B: Thrombocytopenia. I. Incidence and aetiology. Acta Med. Scand. (1972) 191(6):535-540.
2. KAUSHANSKY K: The thrombocytopenia of cancer. Prospects for effective cytokine therapy. Hematol. Oncol. Clin. North Am. (1996) 10(2):431-455.
3. PROW D, VADHAN-RAJ S: Thrombopoietin: biology and potential clinical applications. Oncology (Williston Park) (1998) 12(11): 1597-1604, 1607-1598; discussion 1611-1594.
4. ALVAREZ JM, GATES R, ROWE D, BRADY PW: Complications from intra-aortic balloon counterpulsation: a review of 303 cardiac surgical patients. Eur. J. Cardiothorac. Surg. (1992) 6(10):530-535.
5. VONDERHEIDE RH, THADHANI R, KUTER DJ: Association of thrombocytopenia with the use of intra-aortic balloon pumps. Am. J. Med. (1998) 105(1):27-32.
6. KRUSKALL MS: The perils of platelet transfusions. N. Engl. J. Med. (1997) 337(26):1914-1915.
7. MCCULLOUGH J: Current issues with platelet transfusion in patients with cancer. Semin. Hematol. (2000) 37(2 Suppl. 4):3-10.
8. GEORGE JN, WOOLF SH, RASKOB GE et al.: Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood (1996) 88(1):3-40.
9. SOUYRI M, VIGON I, PENCIOLELLI JF et al.: A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell (1990) 63(6):1137-1147.
10. VIGON I, MORNON JP, COCAULT L et al.: Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc. Natl. Acad. Sci. USA (1992) 89(12):5640-5644.
11. KAUSHANSKY K, LOK S, HOLLY RD et al.: Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature (1994) 369(6481):568-571.
12. LOK S, KAUSHANSKY K, HOLLY RD et al.: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature (1994) 369(6481):565-568.
13. BASSER RL, O'FLAHERTY E, GREEN M et al.: Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood (2002) 99(7):2599-2602.
14. LI J, YANG C, XIA Y et al.: Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood (2001) 98(12):3241-3248.
15. LABER EG, BEGLEY CG: Small-Molecule and Peptide Agonists: A Literature Review. Laber EG, Begley CG (Eds), Humana Press, Inc., Totowa, NJ, USA (2003):65-80.
16. BUSSEL JB, KUTER DJ, GEORGE JN et al.: Stimulating thrombopoiesis with AMG 531 improves platelet counts in patients with immune thrombocytopenic purpura. N. Engl. J. Med. (2006) (In Press).
17. CWIRLA SE, BALASUBRAMANIAN P, DUFFIN DJ et al.: Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science (1997) 276(5319):1696-1699.
18. DOWER WJ, CWIRLA SE, BALASUBRAMANIAN P et al.: Peptide agonists of the thrombopoietin receptor. Stem Cells (1998) 16(Suppl. 2):21-29.
19. ERICKSON-MILLER CL, DELORME E, TIAN SS et al.: Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp. Hematol. (2005) 33(1):85-93.
20. INAGAKI K, ODA T, NAKA Y et al.: Induction of megakaryocytopoiesis and thrombocytopoiesis by JTZ-132, a novel small molecule with thrombopoietin mimetic activities. Blood (2004) 104(1):58-64.
21. WANG B, NICHOL JL, SULLIVAN JT: Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin. Pharmacol. Ther. (2004) 76(6):628-638.
22. JENKINS J, NICHOLL R, WILLIAMS D et al.: An oral, non-peptide, small molecule throbopoietin receptor agonist increases platelet counts in healthy subjects. Blood (2005) 106:797a.
23. KUTER DJ, BEGLEY CG: Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood (2002) 100(10):3457-3469.
24. SZILVASSY SJ: The biology of hematopoietic stem cells. Arch. Med. Res. (2003) 34(6):446-460.
25. DEBILI N, COULOMBEL L, CROISILLE L et al.: Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow. Blood (1996) 88(4):1284-1296.
26. NAKORN TN, MIYAMOTO T, WEISSMAN IL: Characterization of mouse clonogenic megakaryocyte progenitors. Proc. Natl. Acad. Sci. USA (2003) 100(1):205-210.
27. CAJANO A, POLOSA P: [Contribution to the study of the morphology of megakaryocytes and blood platelets with Feulgens test.]. Haematologica (1950) 34(10):1113-1121.
28. ODELL TT JR, JACKSON CW, GOSSLEE DG: Maturation of rat megakaryocytes studied by microspectrophotometric measurement of DNA. Proc. Soc. Exp. Biol. Med. (1965) 119(4):1194-1199.
29. SCHMITT A, GUICHARD J, MASSE JM, DEBILI N, CRAMER EM: Of mice and men: comparison of the ultrastructure of megakaryocytes and platelets. Exp. Hematol. (2001) 29(11):1295-1302.
30. CRONKITE EP, BOND VP, FLIEDNERTM, PAGLIA DA, ADAMIK ER: Studies on the Origin, Production and Destruction of Platelets. Johnson SA, Monto RW, Rebuck JW, Horn RC (Eds), Little, Brown and Co., Boston, MA, USA (1961):595-609.
31. LONG MW: Megakaryocyte differentiation events. Semin. Hematol. (1998) 35(3):192-199.
32. GORDON MS, HOFFMAN R: Growth factors affecting human thrombocytopoiesis: potential agents for the treatment of thrombocytopenia. Blood (1992) 80(2):302-307.
33. VAINCHENKER W, DEBILI N, MOUTHON MA, WENDLING F: Megakaryocytopoiesis: cellular aspects and regulation. Crit. Rev. Oncol. Hematol. (1995) 20(1-2):165-192.
34. PANG L, WEISS MJ, PONCZ M: Megakaryocyte biology and related disorders. J. Clin. Invest. (2005) 115(12):3332-3338.
35. D'HONDT V, HUMBLET Y, GUILLAUME T et al.: Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized Phase Ib study. Blood (1995) 85(9):2347-2353.
36. GORDON MS, MCCASKILL-STEVENS WJ, BATTIATO LA et al.: A Phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood (1996) 87(9):3615-3624.
37. LEONARDI V, DANOVA M, FINCATO G, PALMERI S: Interleukin 3 in the treatment of chemotherapy induced thrombocytopenia. Oncol. Rep. (1998) 5(6):1459-1464.
38. VADHAN-RAJ S, KUDELKA AP, GARRISON L et al.: Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J. Clin. Oncol. (1994) 12(4):707-714.
39. DU X, WILLIAMS DA: Interleukin-11: review of molecular, cell biology, and clinical use. Blood (1997) 89(11):3897-3908.
40. NEUMEGA: Oprelvekin [package insert]. Genetics Institute, Inc., Cambridge, MA, USA (2002).
41. KAUSHANSKY K: The molecular mechanisms that control thrombopoiesis. J. Clin. Invest. (2005) 115(12):3339-3347.
42. KAUSHANSKY K, DRACHMAN JG: The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene (2002) 21(21):3359-3367.
43. STOFFEL R, WIESTNER A, SKODA RC: Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood (1996) 87(2):567-573.
44. YANG C, LI YC, KUTER DJ: The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat. Br. J. Haematol. (1999) 105(2):478-485.
45. FIELDER PJ, GURNEY AL, STEFANICH E et al.: Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood (1996) 87(6):2154-2161.
46. KUTER DJ, ROSENBERG RD: The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood (1995) 85(10):2720-2730.
47. BROUDY VC, LIN NL, KAUSHANSKY K: Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood (1995) 85(7):1719-1726.
48. KUTER DJ, BEELER DL, ROSENBERG RD: The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc. Natl. Acad. Sci. USA (1994) 91(23):11104-11108.
49. ALEXANDER WS, ROBERTS AW, NICOLA NA, LI R, METCALF D: Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood (1996) 87(6):2162-2170.
50. CARVER-MOORE K, BROXMEYER HE, LUOH SM et al.: Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice. Blood (1996) 88(3):803-808.
51. GURNEY AL, CARVER-MOORE K, DE SAUVAGE FJ, MOORE MW: Thrombocytopenia in c-mpl-deficient mice. Blood (1994) 265(5177):1445-l447.
52. LI J, KUTER DJ: The end is just the beginning: megakaryocyte apoptosis and platelet release. Int. J. Hematol. (2001) 74(4):365-374.
53. CHOI ES, HOKOM MM, CHEN JL et al.: The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. Br. J. Haematol. (1996) 95(2):227-233.
54. KIMURA S, ROBERTS AW, METCALF D, ALEXANDER WS: Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc. Natl. Acad. Sci. USA (1998) 95(3):1195-1200.
55. KIRITO K, FOX N, KAUSHANSKY K: Thrombopoietin induces HOXA9 nuclear transport in immature hematopoietic cells: potential mechanism by which the hormone favorably affects hematopoietic stem cells. Mol. Cell. Biol. (2004) 24(15):6751-6762.
56. KIRITO K, FOX N, KOMATSU N, KAUSHANSKY K: Thrombopoietin enhances expression of vascular endothelial growth factor (VEGF) in primitive hematopoietic cells through induction of HIF-lalpha. Blood (2005) 105(11):4258-4263.
57. HOKOM MM, LACEY D, KINSTLER OB et al.: Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood (1995) 86(12):4486-4492.
58. BEGLEY CG, BASSER RL: Biologic and structural differences of thrombopoietic growth factors. Semin. Hematol. (2000) 37(2 Suppl. 4):19-27.
59. SHERIDAN WP, KUTER DJ: Mechanism of action and clinical trials of Mpl ligand. Curr. Opin. Hematol. (1997) 4(5):312-316.
60. BASSER RL, RASKO JE, CLARKE K et al.: Randomized, blinded, placebo-controlled Phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood (1997) 89(9):3118-3128.
61. BASSER RL, RASKO JE, CLARKE K et al.: Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet (1996) 348(9037):1279-1281.
62. BASSER RL, UNDERHILL C, DAVIS I et al.: Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J. Clin. Oncol (2000) 18(15):2852-2861.
63. FANUCCHI M, GLASPY J, CRAWFORD J et al.: Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N. Engl. J. Med. (1997) 336(6):404-409.
64. VADHAN-RAJ S, VERSCHRAEGEN CF, BUESO-RAMOS C et al.: Recombinant human chrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann. Intern. Med. (2000) 132(5):364-368.
65. NOMURA S, DAN K, HOTTA T, FUJIMURA K, IKEDA Y: Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood (2002) 100(2):728-730.
66. RICE L, NICHOL JL, MCMILLAN R, ROSKOS LK, BACILE M: Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am. J. Hematol. (2001) 68(3):210-214.
67. BALLEM PJ, SEGAL GM, STRATTON JR et al.: Mechanisms of thrombocyropenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J. Clin. Invest. (1987) 80(1):33-40.
68. CHANG M, NAKAGAWA PA, WILLIAMS SA et al.: Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in film. Blood (2003) 102(3):887-895.
69. HEYNS ADU P, BADENHORST PN, LOTTER MG et al.: Platelet turnover and kinetics in immune thrombocytopenic purpura: results with autologous 111In-labeled platelets and homologous 51Cr-labeled platelets differ. Blood (1986) 67(1):86-92.
70. ICHIKAWA N, ISHIDA F, SHIMODAIRA S et al.: Regulation of serum thrombopoietin levels by platelets and megakaryocytes patients with aplastic anaemia and idiopathic thrombocytopenic purpura. Thromb. Haemost. (1996) 76(2):156-160.
71. ARCHIMBAUD E, OTTMANN OG, YIN JA et al.: A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood (1999) 94(11):3694-3701.
72. NASH RA, KURZROCK R, DIPERSIO J et al.: A Phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. (2000) 6(1):25-34.
73. SCHIFFER CA, MILLER K, LARSON RA et al.: A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood (2000) 95(8):2530-2535.
74. BOGER DL, GOLDBERG J: Cytokine receptor dimerization and activation: prospects for small molecule agonists. Bioorg. Med. Chem. (2001) 9(3):557-562.
75. BROUDY VC, LIN NL: AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine (2004) 25(2):52-60.
76. ERICKSON-MILLER CL, DELORME E, GIAMPA L et al.: Biological activity and selectivity for TPO receptor of the orally bioavailable, small molecule TPO receptor agonist, SB-497115. Blood (2005) 106:796a.
77. BUSSEL JB, KUTER DJ, GEORGE JN et al.: Long-term dosing of AMG 531 is effective and well tolerated in thrombocytopenic patiens with immune thrombocytopenic purpura. Blood (2005) 106(11):220.
78. NEWLAND A, CAULIER MT, SCHIPPERUS MR et al.: An open-label, unit dose-finding study evaluationg the safety and platelet response of a novel throbopoietic protein (AMG531) in thrombocytopenic adul patients (Pts) with immune thrombocytopenic purpura (ITP). Blood (2004) 104(11):2058.
79. BRUNSTEIN CG, WAGNER JE: Umbilical cord blood transplantation and banking. Annu. Rev. Med. (2006) 57:403-417.
80. GLUCKMAN E, LOCATELLI F: Umbilical cord blood transplants. Curr. Opin. Hematol. (2000) 7(6):353-357.
81. RUBINSTEIN P, CARRIER C, SCARADAVOU A et al.: Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N. Engl. J. Med. (1998) 339(22):1565-1577.
82. PIACIBELLO W, SANAVIO F, GARETTO L et al.: Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood (1997) 89(8):2644-2653.
83. PIACIBELLO W, SANAVIO F, GARETTO L et al.: Differential growth factor requirement of primitive cord blood hematopoietic stem cell for self-renewal and amplification versus proliferation and differentiation. Leukemia (1998) 12(5):718-727.
84. PIACIBELLO W, SANAVIO F, SEVERINO A et al.: Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. Blood (1999) 93(11):3736-3749.
85. BRUNO S, GUNETTI M, GAMMAITONI L et al.: Fast but durable megakaryocyte repopulation and platelet production in NOD/SCID mice transplanted with ex-vivo expanded human cord blood CD34+ cells. Stem Cells (2004) 22(2):135-143.
86. BERTOLINI F, BATTAGLIA M, PEDRAZZOLI P et al.: Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. Blood (1997) 89(8):2679-2688.
87. RATAJCZAK MZ, RATAJCZAK J, MACHALINSKI B, MICK R, GEWIRTZ AM: In vitro and in vivo evidence that ex vivo cytokine priming of donor marrow cells may ameliorate posttransplant thrombocytopenia. Blood (1998) 91(1):353-359.
88. FOX N, PRIESTLEY G, PAPAYANNOPOULOU T, KAUSHANSKY K: Thrombopoietin expands hematopoietic stem cells after transplantation. J. Clin. Invest. (2002) 110(3):389-394.